Diphtheria News and Research

RSS

Diphtheria is a disease caused by a bacterium, Corynebacterium diphtheriae, that usually affects the tonsils, throat, nose and/or skin. It is passed from person to person by droplet transmission, usually by breathing in diphtheria bacteria after an infected person has coughed or sneezed. Although diphtheria disease is rare in the U.S., it appears that C diphtheriae continues to circulate in areas of the country with previously endemic diphtheria. Diphtheria also occurs in many other parts of the world.

GAVI calls meeting with existing, potential donors

The GAVI Alliance has "asked existing and potential donors to a meeting in The Hague on March 25 and 26 to challenge them to 'make a strong impact' on childhood death rates," Reuters reports. "GAVI, which is supported by the World Health Organization, the World Bank, UNICEF, the Bill & Melinda Gates Foundation and vaccine makers, says it has 40 percent of the $7 billion it needs between now and 2015 to help" immunize of millions of children in developing countries by 2015, according to the news service.

16 Mar 2010

Supreme Court to hear case on vaccine side effects

The Associated Press: The Supreme Court will hear a case to decide whether drug makers can be sued by families who claim their children have suffered health problems from vaccines, going against a 1986 federal law that shields drug makers from most lawsuits and instead sets up a federal vaccine court to handle disputes.

10 Mar 2010

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine

Pfizer Inc. announced today that the United States Food and Drug Administration has granted approval for Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company’s 13-valent pneumococcal conjugate vaccine.

25 Feb 2010

Researchers develop technology to preserve vaccines in tropical temperatures

A team of British researchers have developed a simple, low-cost method to preserve vaccines in tropical climates, which they say could help to revolutionalize vaccination campaigns in developing countries, Reuters reports.

19 Feb 2010

American Red Cross raises $32M in mobile giving for ongoing relief efforts in Haiti

Hundreds of thousands of cell phone users have made $10 donations to the American Red Cross Haiti Relief and Development Fund by sending the word "Haiti" to 90999, raising a record-shattering $32 million in mobile giving for the ongoing relief efforts.

12 Feb 2010

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Commenting on the Group's 2009 performance, sanofi-aventis Chief Executive Officer Christopher A. Viehbacher said, "2009 was the first year of implementation of our new strategy. Major steps have already been achieved in strengthening our growth platforms and reinforcing our R&D pipeline while delivering a double-digit EPS(1) growth".

10 Feb 2010

New report finds low adult vaccination rates in U.S.

A new report, Adult Immunization: Shots to Save Lives, released today by the Trust for America's Health (TFAH), the Infectious Diseases Society of America (IDSA), and the Robert Wood Johnson Foundation (RWJF) found that more than 30 percent of adults ages 65 and older had not been immunized against pneumonia in 36 states as of 2008.

5 Feb 2010

Despite improvements, aid delivery bottlenecks persist in Haiti

Three weeks after a major earthquake struck Haiti, challenges in getting aid to those in need persist, the Washington Post reports. "Rajiv Shah, the administrator of the U.S. Agency for International Development, said the relief effort has escalated in recent days and will continue to do so.

4 Feb 2010

At World Economic Forum, Gates Foundation announces 10-year, $10B vaccine commitment

Bill and Melinda Gates announced Friday during the World Economic Forum in Davos, Switzerland, that their foundation would commit $10 billion over the next decade to research, develop and deliver vaccines for the world's poorest countries, the New York Times reports (McNeil, 1/29). The Gateses "said they hope the commitment would spur support by governments, corporations, and other donors for vaccinations efforts," the Chronicle of Philanthropy writes (Wilhelm, 1/29).

30 Jan 2010

Vaccination for children: Pros and cons

ProCon.org, a nonpartisan 501(c)3 nonprofit public charity dedicated to promoting critical thinking, created the new website http://vaccines.procon.org to explore the core question "Should any vaccines be required for children?"

23 Jan 2010

Statins may protect SCD children from pneumococcal infection

New research suggests a family of widely used cholesterol-lowering drugs might help protect individuals from serious illness following bacterial infection, including the pneumococcal infections that pose a deadly threat to those with sickle cell disease.

20 Jan 2010

Aid begins flowing into Haiti, up to 3m may be affected

"Aid started flowing into Haiti Wednesday in the wake of the earthquake that slammed the impoverished nation late Tuesday afternoon," CNN reports. "One of two [U.S] military cargo planes carrying a 30-man assessment team arrived at Port-au-Prince airport Wednesday evening to assess Haiti's needs."

17 Jan 2010

H1N1 flu vaccines and other resources for remaining healthy to be offered at Pennsylvania Farm Show

The Department of Health is offering free H1N1 flu vaccines and other resources for remaining healthy at its exhibit at the Pennsylvania Farm Show, which runs through Jan. 16.

12 Jan 2010

Study explains how H. pylori infection causes stomach cancer

Researchers report that Helicobacter pylori, the only bacterium known to survive in the harsh environment of the human stomach, directly activates an enzyme in host cells that has been associated with several types of cancer, including gastric cancer.

7 Jan 2010

CDC and AAFP recommend whooping cough vaccine for adults and adolescents

Many people may think of whooping cough as a disease of the past -- something eradicated generations ago. However, the number of cases reported by the Centers for Disease Control and Prevention (CDC) indicate that whooping cough (pertussis) is still very much a public health concern; health experts estimate that up to 600,000 cases occur each year in adults alone. In fact, whooping cough cases are on the rise in San Diego

6 Jan 2010

Children’s vaccination coverage rises substantially in U.S.

About three-quarters of U.S. children received recommended vaccinations in 2008, up from about half in 2000, reports a new study from the Centers for Disease Control and Prevention (CDC).

5 Jan 2010

Pfizer provides update on Prevnar 13

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has not yet completed its review of the Biologics License Application (BLA) for Prevnar 13™, (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company’s candidate 13-valent pneumococcal conjugate vaccine.

31 Dec 2009

Health Canada approves Prevnar 13 vaccine for invasive pneumococcal disease

Following a Priority Review, Health Canada has approved Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)) for children aged six weeks through five years for active immunization against invasive pneumococcal disease, a bacterial infection that can include meningitis (inflammation of the coverings of the brain and spinal cord), sepsis (bloodstream infection), bacteremic pneumonia, pleural empyema (accumulation of pus in the cavity surrounding the lungs) and bacteremia (bacteria in the blood).

22 Dec 2009

Akorn exits vaccine distribution business

Akorn, Inc. today announced that it failed to reach an amicable resolution to a longer term and strategic business arrangement with the supplier of its Tetanus Diphtheria (“Td”) vaccine and as a result will be exiting the business. The existing supply agreement will end on March 14, 2010. The company previously announced its intent to exit the distribution of flu vaccines.

19 Dec 2009

Pfizer's Prevenar 13 granted European marketing authorization

The European Commission has granted Pfizer Inc. a European marketing authorization for its pneumococcal conjugate vaccine, Prevenar 13 (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent, adsorbed]). Prevenar 13 is indicated for active immunization for the prevention of invasive disease, pneumonia, and acute otitis media caused by 13 Streptococcus pneumoniae serotypes in infants and children from 6 weeks to 5 years of age. Invasive pneumococcal disease includes sepsis, meningitis, bacteremia, bacteremic pneumonia, and empyema.

11 Dec 2009